The left dorsolateral prefrontal cortex (DLPFC) is involved in the experience and modulation of pain, and may be an important node linking pain and cognition. Repetitive transcranial magnetic stimulation (rTMS) to the left DLPFC can reduce chronic and experimental pain. However, whether left DLPFC rTMS can influence the development of chronic pain is unknown. Using repeated intramuscular injection of nerve growth factor to induce the development of sustained muscle pain (lasting weeks), 30 healthy individuals were randomized to receive 5 consecutive daily treatments of active or sham left DLPFC rTMS, starting before the first nerve growth factor injection on day 0. Muscle soreness and pain severity were collected daily for 14 days and disability on every alternate day. Before the first and 1 day after the last rTMS session, anxiety, depression, affect, pain catastrophizing, and cognitive performance on the attention network test were assessed. Left DLPFC rTMS treatment compared with sham was associated with reduced muscle soreness, pain intensity, and painful area (P , 0.05), and a similar trend was observed for disability. These effects were most evident during the days rTMS was applied lasting up to 3 days after intervention. Depression, anxiety, pain catastrophizing, and affect were unchanged. There was a trend toward improved cognitive function with rTMS compared with sham (P 5 0.057). These data indicate that repeated left DLPFC rTMS reduces the pain severity in a model of prolonged muscle pain. The findings may have implications for the development of sustained pain in clinical populations.
Introduction
Musculoskeletal pain disorders are the largest contributors to global years lived with disability. 23 Consequently, effective and affordable strategies are urgently required to deal with this rising problem.
Our previous work has demonstrated disruption of brain cognitive networks with acute pain and with chronic pain, 12, 13, 31, 35, 37, 38 and we further proposed a role for cognitive network dysfunction in chronic pain disorders and possible treatments. 34 The dorsolateral prefrontal cortex (DLPFC)-particularly the left DLPFC-has been implicated in pain experience and modulation and could be a major node mediating the interaction between pain and cognition. 36 For example, patients have shown altered abnormal cognitive-related activity in the left DLPFC when performing conflict tasks such as the attention network test. 31, 38 This suggests that targeting DLPFC function could have effects on both pain and cognitive function, as well as their interaction.
Repetitive transcranial magnetic stimulation (rTMS) of the left DLPFC has been used with some success for the treatment of chronic pain conditions including migraine, 11 burning mouth syndrome, 47 post-traumatic headache, 27 postoperative pain, 8, 9 and fibromyalgia where analgesic effects were similar to those of Food and Drug Administration-approved pharmaceuticals with fewer side effects. 30 Left DLPFC rTMS has an immediate analgesic effect for prolonged capsaicin-induced pain in healthy subjects, and the mechanisms of action seem to depend on widespread cortical network effects and activation of the endogenous opioid system. 45, 46 Left DLPFC rTMS also modulates dopaminergic 14 and serotonergic systems, 39 which could also potentially modulate pain. Right DLPFC rTMS analgesia does not involve an endogenous opioid mechanism 17 and might be related to glutamatergic modulation. 16 Left-but not right-DLPFC rTMS reduced bilateral capsaicin pain intensity when delivered 10 to 20 minutes after capsaicin application, and the analgesic effects was found after 20 to 30 minutes. 10, 45, 46 In line with this finding, left DLPFC rTMS increased heat pain thresholds and reduced heat hyperalgesia by capsaicin, but had no effect on cold pain thresholds. 46 Left DLPFC rTMS has also been shown to reverse motor cortex inhibition during capsaicininduced pain in healthy participants. 22 However, the mechanisms of rTMS for pain are still the subject of considerable Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
debate, 20 in particular, regarding the timing of rTMS with respect to the nociceptive event, type of pain, and duration of the analgesic effect.
Pain models have been used to study the effects of pain lasting minutes to hours (eg, topical capsaicin) in healthy participants. However, to understand the development of sustained muscle pain, longer-lasting prolonged pain models are needed. Intramuscular injections of nerve growth factor (NGF) induce deeptissue pain and hyperalgesia for days to weeks 1, 4, 44 with motor cortical adaptations. 25, 33 In this study, we randomized healthy subjects to receive left DLPFC rTMS over 5 days or sham rTMS to test whether rTMS could reduce pain intensity and distribution, as well as improve cognitive task performance, in a long-lasting (up to 14 days) model of NGF-induced muscle pain. We hypothesized that left DLPFC rTMS would reduce prolonged muscle pain and improve performance on a cognitive task, relative to sham.
Materials and methods

Participants
Thirty healthy right-handed subjects (18 female; 12 male) participated in this randomized controlled study, recruited through online advertising and flyers posted at Aalborg University. All participants were naive to single pulse and rTMS before enrolment and had no history of chronic pain, neurological disorders, and psychiatric disorders. Fifteen participants (9 women for each group) were randomly assigned to each of the active or sham rTMS groups. Inclusion criteria: healthy men and women aged 21 to 50 years; speak and understand English. Exclusion criteria: pregnancy; drug addiction defined as the use of cannabis, opioids, or other drugs; previous neurologic, musculoskeletal, or mental illnesses; lack of ability to cooperate; history of chronic pain or current acute pain; previous experience with rTMS; contraindications to rTMS application (history of epilepsy, metal in the head or jaw, etc.); and failure to pass the Transcranial Magnetic Stimulation Adult Safety Screen (Rossi et al., 2011). Before starting experimental procedures, a physical examination was performed to check the presence of full painfree range of elbow and wrist motion, and the absence of tenderness to palpation of the soft tissues in the extensor muscles of the wrist. The study was approved by the local Ethics Committee (N-20170041) and was performed in accordance with the Helsinki Declaration. Written informed consent was obtained before study commencement.
Study protocol
The study involved 6 sessions on 6 consecutive days (day 0-5), plus online daily diaries completed up to day 14. Randomization occurred on day 0 before any assessments. Randomization was based on a predetermined, randomly generated order. Questionnaires were collected at the beginning of the sessions on days 0 and 5. Other data collected as part of the protocol that will be reported elsewhere include motor-evoked potentials, somatosensory-evoked potentials, electroencephalography during cognitive task performance, quantitative sensory, and motor assessment (pressure pain thresholds and wrist extensor force). On day 0 and 2, participants received an injection of NGF into the right extensor radialis carpi brevis (ECRB) muscle to develop muscle pain along the radial site of the right forearm. After assessments at day 0, 1, 2, 3, and 4, participants received 20 minutes of active or sham high-frequency rTMS on the DLPFC. On day 0 and 2, the real or sham rTMS occurred before the NGF injection.
Questionnaires
At day 0 and day 5, participants completed the following questionnaires: (1) State-Trait Anxiety Inventory (STAI-S, STAI-T) 41 ; (2) Pain Catastrophizing Scale 42, 43 ; (3) Beck Depression Inventory 3 ; and (4) Positive and Negative Affective Schedule. 15, 48 The area of pain was assessed using body chart drawings at days 1 to 5, 9, and 14. 40 Participants drew the distribution of their NGF-induced pain on an anatomical drawing of the upper limb. The areas of the body chart drawings were calculated in arbitrary units (a.u.) using a scanning program (VistaMetrix, v.1.38.0; SkillCrest, LLC, Tucson, AZ).
Online diaries regarding muscle soreness and pain severity were completed on days 0 to 14. Muscle soreness was assessed using a modified 7-point Likert scale; 0 5 "a complete absence of soreness," 1 5 "a light soreness in the muscle felt only when touched/vague ache," 2 5 "a moderate soreness felt only when touched/a slight persistent ache," 3 5 "a light muscle soreness when lifting or carrying objects," 4 5 "a light muscle soreness, stiffness, or weakness when moving the wrist without gripping an object," 5 5 "a moderate muscle soreness, stiffness, or weakness when moving the wrist," 6 5 "a severe muscle soreness, stiffness, or weakness that limits the ability to move." Pain severity was assessed on a 11-point Numerical Rating Scale (NRS) (0 5 no pain and 10 5 most intense pain imaginable). The Patient-rated Tennis Elbow Evaluation Questionnaire (PRTEEQ 29 ) used to assess average pain and disability of the injected arm, was completed on days 0, 3, 5, 9, and 14.
Repetitive transcranial magnetic stimulation procedures
Repetitive transcranial magnetic stimulation was delivered using a figure-of-eight-shaped coil (70-mm Double Air Film Coil; Magstim Super Rapid2 Plus1, Magstim Co, Ltd, Dyfed, United Kingdom). The rTMS protocol consisted of 1 session per day for 5 consecutive days. Each 20-minute stimulation session consisted of 80 trains of 5-second pulses with a frequency of 10 Hz and an interval of 10 seconds between each train, giving a total of 4000 pulses per day. 46 The stimulation intensity was 110% of the resting motor threshold (rMT) of the first dorsal interosseous muscle, and the coil was located according to the BeamF3 algorithm.
2,32 The BeamF3 algorithm takes as input 3 scalp measurements: the nasion-inion distance, the left tragus-right tragus distance through the scalp vertex, and the head circumference measured through the FPz-Oz plane in the international 10 to 20 EEG system. These values were entered into the freely available BeamF3 desktop application (clinicalresearcher.org/software.htm) to generate the coordinates to locate the rTMS coil. Sham stimulation was performed with a sham coil of identical size, color, and shape, emitting a sound similar to that emitted by the active coil (70-mm double air film sham coil). Procedures and instructions to participants in the rTMS and sham groups were identical. Because the rTMS procedure is known to be painful, pain ratings were acquired at the end of each rTMS/ sham session, 7 using a 0 to 10 NRS for pain intensity, where 0 was no pain and 10 was most intense pain imaginable.
Nerve growth factor-induced muscle soreness
Muscle pain and hyperalgesia were induced by repeated injection of NGF into the ECRB muscle, which models lateral www.painjournalonline.com 2487 epicondylalgia. 4 Sterile solutions of recombinant human beta-NGF were prepared by the pharmacy (Skanderborg Apotek, Skanderborg, Denmark). Nerve growth factor injections occurred on day 0 and 2. The site of injection was cleaned with alcohol, and NGF solution (5 mg/0.5 mL) was injected into the muscle belly of ECRB, guided in-plane under real-time ultrasound guidance (SonoSite M-Turbo; FUJIFILM SonoSite, Inc).
Cognitive task
Participants performed the Attention Networks Test 21 on day 0 and 5. This task assesses cognitive function in 3 domains: alerting, orienting, and executive function (conflict resolution). Participants performed the task in 6 blocks of 5 minutes according to the procedure previously reported. 21 Briefly, the task implemented in E-prime (version 3.0) involves the presentation of an arrow, and the correct response is the direction of that arrow, indicated by the button on the participant's righthand middle (right) or index (left) finger. Around the arrow, 2 arrows can be presented on each side, which can point in the same direction (congruent) or opposite direction (incongruent) of the center target arrow. Additional cues are given before the target stimuli and are related to alerting in orienting. Reaction times were used as the performance measure in the task. Only the conflict (difference between congruent and incongruent reaction time) was examined because these measures previously have been reported in the context of acute and chronic pain, 31, 37, 38 where increased brain resources have been shown to be recruited.
Statistical analysis
All data are presented as mean and SEM. All data from all assessments were normality tested using visual inspection and the Shapiro-Wilk test. A mixed-model analysis of variance was used for all parameters to assess effects of day (days 0-14 for muscle soreness and pain intensity, and days 0, 5, 9, and 14 for other measures), group (rTMS and sham), and day-by-group interaction, where the factor day was repeated-measures, and group was between group comparisons. For procedural NRS pain scores, a 1-way repeated-measure analysis of variance was used with time as main factor. We further tested the association between procedural pain and muscle soreness and pain intensity the next day using Pearson correlations. Correcting against violations of sphericity, the Greenhouse-Geisser approach was used. Effect sizes (partial eta-squared [h 2 p ]) are reported for significant effects. Where appropriate, post hoc analyses were performed using Bonferroni multiple comparison tests. Statistical significance was set at P , 0.05.
Results
Demographics
The sample sizes, sex, age, height, and weight for the sham and active groups are shown in Table 1 . Groups were matched for sex (6 men and 9 women in each group). All subjects performed all sessions, and no data were missing. Resting motor threshold assessed on days 0 and 5 were (mean 6 SD) sham day 0, 42.9 6 10.0, sham day 5, 41.7 6 8.7, active day 0, 42.9 6 11.0, and active day 5, 43.9 6 9.6.
Left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation reduced pain and muscle soreness
Mean values and SDs for all outcomes are reported in Supplementary Table S1 (available at http://links.lww.com/ PAIN/A636). The rTMS group had lower muscle soreness ratings (group main effect: F 1,28 5 8.8, P 5 0.006, h Fig. 1B) than the sham group. Post hoc tests revealed that differences in muscle soreness Likert scores were apparent at 2, 4, 5, 6, and 7 days after the first NGF injection, (P , 0.05). Because these Likert score data were non-normally distributed, we also performed KruskalWallis tests and found the same as the parametric tests (ie, days 2, 4, 5, 6, and 7 were different between groups). The rTMS group also had a similar, but nonsignificant trend toward reduced disability as assessed by the Patient-rated Tennis Elbow Evaluation Questionnaire, which was apparent by day 5 (group main effect: F 1,28 5 2.5, P . 0.1, h Fig. 1D ), and post hoc tests indicated significant differences at days 3 and 5 (P , 0.05).
Left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation showed a trend toward improved cognitive task performance
The rTMS group had a marginally greater reduction in conflict cost (ie, improved performance in reaction time) compared with sham at day 5 compared with baseline (group main effect: F 1,28 5 1.1, Table 1 .
Repetitive transcranial magnetic stimulation procedural pain
The rTMS intensity used in this study was 60.1 6 2.5. Procedural NRS pain ratings and rTMS intensity correlated (Pearson r 5 0.56, P , 0.05). Procedural NRS pain ratings steadily decreased across days, from 5.6 6 0.8 on day 0 to 4.2 6 0.7, 3.8 6 0.6, 3.5 6 0.6, and 2.9 6 0.6 for days 1 through 4, respectively (F 1.87,52 5 8.8, P 5 0.002, h pain with higher procedural pain the previous day. The sham procedure was never painful. No side effects were reported, and the treatment was well-tolerated by all participants.
Discussion
The present results show that 5 days of treatment with left DLPFC high-frequency (excitatory) rTMS can reduce the pain intensity, distribution, and muscle soreness associated with long-lasting experimental muscle pain. Moreover, no significant effect on depression, anxiety, pain catastrophizing, or affect scores was found because of rTMS, although a near-significant improvement in cognitive task performance was observed. The NGF-induced muscle pain model is believed to closely reflect the period of acute pain before the transition to chronic pain. 4, 33 Because pain intensity is a strong predictor of the transition to chronic pain, 26 interventions such as left DLPFC rTMS that reduce pain during the early periods of development have the potential clinical application of preventing the persistent pain after injury or surgery.
Effects of dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation on pain
The mechanisms by which left DLPFC rTMS produce analgesia are yet unclear, but growing evidence points to the left DLPFC as an important region in pain experience and modulation. 36 Although one study has shown that left DLPFC rTMS reduces postoperative pain, the stimulation was performed after surgery. 8 It has yet to be tested whether rTMS before surgery can prevent the development of acute and chronic pain. Left DLPFC rTMS has shown promise for a number of chronic pain conditions, including migraine, 11 post-traumatic headache, 27 fibromyalgia, 30 and burning mouth syndrome; 47 although for central poststroke pain, it has been shown to be ineffective. 18 Left DLPFC rTMS could thus be an effective treatment for pain or pain prevention. In the current study, effects of rTMS were strongest on the later days of intervention and 3 days afterward (ie, days 2-7), whereas minimal differences between active and sham groups were seen late (ie, days [8] [9] [10] [11] [12] [13] [14] . Further studies using DLPFC rTMS are required to determine whether a longer intervention period would have longer-lasting effects. One mechanism of left DLPFC rTMS analgesia could be activation of the descending modulatory endogenous opioidergic system, 45, 46 although the involvement of glutamatergic, dopaminergic, and serotonergic systems is also plausible. 14, 16, 39 High-frequency rTMS of the left DLPFC is an effective treatment for major depressive disorder. 24 The effects on mood present another means by which left DLPFC rTMS could have analgesic effects. 5, 6, 27, 49 We found no effect of left DLPFC rTMS on positive or negative affect, anxiety, or depression, which could have been a result of either the low scores on these questionnaires given the healthy participants involved, or the shorter period of intervention compared with typical clinical protocols for depression (weeks).
Effects of dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation on cognitive function
Another possibility is that the analgesic effects derived from left DLPFC rTMS occur through modulation of cognitive function. 34, 36 Previous work has shown the left DLPFC stimulation can modulate cognitive function. For example, a recent study reported that transcranial direct current stimulation over the left DLPFC improved performance on a working memory task, which was also associated with a reduction in simultaneous pain evoked with an electrical stimulus. 19 Improved performance on a Stroop task was also reported after 7 days of high frequency left DLPFC rTMS. 28 We therefore assessed cognitive function on a similar cognitive task involving cognitive conflict and found that left DLPFC rTMS was associated with an improvement in cognitive task performance compared with sham, although this effect failed to reach statistical significance, possibly because the stimulation was not repeated for enough days or the sample size was too small. Previous work has shown that in chronic pain conditions, cognitive-related activation of the left DLPFC is increased relative to healthy controls, 31, 38 and after treatment, activation and connectivity of the left DLPFC normalizes. 13, 38 Although the relationship between left DLPFC function and pain is unclear, more extensive follow-up studies on the interaction between DLPFC stimulation, cognitive function, and pain are warranted.
Limitations
There were some notable limitations to the study. First, although our sample size was greater than in previous studies on left DLPFC rTMS for acute 46 or chronic 47 pain, it was fairly small. Although the main outcomes of the study were significant, others, such as disability and cognitive function, showed a nonsignificant trend. These effects are likely to reach significance with a slightly larger sample. Second, as has been reported previously, DLPFC rTMS is painful. 7 We observed similar procedural pain intensity and decrease in procedural pain over time as previously reported. 7, 47 This reduction over time has been interpreted as an analgesic effect of the rTMS rather than habituation to the stimulation over time because the sham procedural pain evoked with electrical stimulation below the sham coil in that study did not show a change over time. 7 In addition, because our measures of pain related to the NGF were acquired a day after intervention, it seems unlikely that differences between sham and rTMS would be related to procedural pain. Another possible limitation is that the stimulation we used was at 110% of the baseline rMT, rather than reacquiring rMT at each session. This is similar to other protocols. 28 Although rMT is likely to change with the NGF model, whether this affects DLPFC response is unknown. A final limitation is that the study was single blind: although participants did not know whether they received real or sham rTMS, the experimenter involved in data collection was not blinded.
Conclusion
Five days of left DLPFC rTMS reduced the development of ongoing pain induced by an NGF muscle pain model compared with the sham rTMS. These changes lasted at least 3 days after the intervention period and occurred in the absence of changes in mood, affect, anxiety, or pain catastrophizing. A trend of improved cognitive performance was also seen in active compared with sham rTMS. Overall, this study provides early evidence for the use of left DLPFC rTMS for preventing the development of pain shortly after tissue trauma.
